Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9379 |
High Similarity |
NPD2533 |
Approved |
0.9379 |
High Similarity |
NPD2534 |
Approved |
0.9379 |
High Similarity |
NPD2532 |
Approved |
0.8966 |
High Similarity |
NPD970 |
Clinical (unspecified phase) |
0.8854 |
High Similarity |
NPD6232 |
Discontinued |
0.8688 |
High Similarity |
NPD7473 |
Discontinued |
0.8645 |
High Similarity |
NPD7819 |
Suspended |
0.8616 |
High Similarity |
NPD5711 |
Approved |
0.8616 |
High Similarity |
NPD5710 |
Approved |
0.8553 |
High Similarity |
NPD6959 |
Discontinued |
0.8493 |
Intermediate Similarity |
NPD1607 |
Approved |
0.8378 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.8378 |
Intermediate Similarity |
NPD1509 |
Clinical (unspecified phase) |
0.8377 |
Intermediate Similarity |
NPD920 |
Approved |
0.8366 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.8365 |
Intermediate Similarity |
NPD3749 |
Approved |
0.8356 |
Intermediate Similarity |
NPD1240 |
Approved |
0.8322 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.8322 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.8291 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.8278 |
Intermediate Similarity |
NPD1243 |
Approved |
0.8278 |
Intermediate Similarity |
NPD2800 |
Approved |
0.8269 |
Intermediate Similarity |
NPD3226 |
Approved |
0.8267 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.8267 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.8247 |
Intermediate Similarity |
NPD642 |
Clinical (unspecified phase) |
0.8242 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.8212 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.8187 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.8165 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.8146 |
Intermediate Similarity |
NPD2346 |
Discontinued |
0.8137 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.8117 |
Intermediate Similarity |
NPD643 |
Clinical (unspecified phase) |
0.8113 |
Intermediate Similarity |
NPD1934 |
Approved |
0.8105 |
Intermediate Similarity |
NPD3750 |
Approved |
0.8101 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.8101 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.8095 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.8075 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.8065 |
Intermediate Similarity |
NPD7390 |
Discontinued |
0.8065 |
Intermediate Similarity |
NPD1511 |
Approved |
0.8063 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.8063 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.8061 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.8012 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7975 |
Intermediate Similarity |
NPD919 |
Approved |
0.7963 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7962 |
Intermediate Similarity |
NPD1512 |
Approved |
0.795 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7949 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7939 |
Intermediate Similarity |
NPD7229 |
Phase 3 |
0.7933 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7931 |
Intermediate Similarity |
NPD1283 |
Approved |
0.7927 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7901 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7898 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7888 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7888 |
Intermediate Similarity |
NPD37 |
Approved |
0.7871 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.7866 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7857 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7853 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7853 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7853 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7852 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7843 |
Intermediate Similarity |
NPD5406 |
Approved |
0.7843 |
Intermediate Similarity |
NPD5404 |
Approved |
0.7843 |
Intermediate Similarity |
NPD5405 |
Approved |
0.7843 |
Intermediate Similarity |
NPD2796 |
Approved |
0.7843 |
Intermediate Similarity |
NPD5408 |
Approved |
0.7806 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7792 |
Intermediate Similarity |
NPD2344 |
Approved |
0.7784 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.7778 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7778 |
Intermediate Similarity |
NPD2799 |
Discontinued |
0.7771 |
Intermediate Similarity |
NPD1247 |
Approved |
0.7756 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.7756 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7733 |
Intermediate Similarity |
NPD3764 |
Approved |
0.7733 |
Intermediate Similarity |
NPD1699 |
Clinical (unspecified phase) |
0.7724 |
Intermediate Similarity |
NPD1281 |
Approved |
0.7719 |
Intermediate Similarity |
NPD5953 |
Discontinued |
0.7706 |
Intermediate Similarity |
NPD7286 |
Phase 2 |
0.7702 |
Intermediate Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.7697 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7673 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.767 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7647 |
Intermediate Similarity |
NPD6651 |
Approved |
0.7643 |
Intermediate Similarity |
NPD7003 |
Approved |
0.7635 |
Intermediate Similarity |
NPD1203 |
Approved |
0.7633 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7633 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7633 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7632 |
Intermediate Similarity |
NPD2979 |
Phase 3 |
0.7632 |
Intermediate Similarity |
NPD943 |
Approved |
0.7616 |
Intermediate Similarity |
NPD2313 |
Discontinued |
0.7613 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7613 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7602 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7595 |
Intermediate Similarity |
NPD2309 |
Approved |
0.7576 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7564 |
Intermediate Similarity |
NPD2343 |
Clinical (unspecified phase) |
0.7558 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7551 |
Intermediate Similarity |
NPD1608 |
Approved |
0.755 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7544 |
Intermediate Similarity |
NPD7228 |
Approved |
0.754 |
Intermediate Similarity |
NPD8151 |
Discontinued |
0.7529 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7529 |
Intermediate Similarity |
NPD4419 |
Clinical (unspecified phase) |
0.7517 |
Intermediate Similarity |
NPD1470 |
Approved |
0.7517 |
Intermediate Similarity |
NPD1164 |
Approved |
0.75 |
Intermediate Similarity |
NPD411 |
Approved |
0.75 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7486 |
Intermediate Similarity |
NPD8312 |
Approved |
0.7486 |
Intermediate Similarity |
NPD8313 |
Approved |
0.7483 |
Intermediate Similarity |
NPD1201 |
Approved |
0.7471 |
Intermediate Similarity |
NPD3926 |
Phase 2 |
0.7469 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7468 |
Intermediate Similarity |
NPD1899 |
Clinical (unspecified phase) |
0.7468 |
Intermediate Similarity |
NPD447 |
Suspended |
0.7466 |
Intermediate Similarity |
NPD4626 |
Approved |
0.7457 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7456 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7453 |
Intermediate Similarity |
NPD7422 |
Clinical (unspecified phase) |
0.7452 |
Intermediate Similarity |
NPD1471 |
Phase 3 |
0.7448 |
Intermediate Similarity |
NPD9545 |
Approved |
0.7442 |
Intermediate Similarity |
NPD7177 |
Discontinued |
0.7442 |
Intermediate Similarity |
NPD7893 |
Clinical (unspecified phase) |
0.7436 |
Intermediate Similarity |
NPD651 |
Clinical (unspecified phase) |
0.7432 |
Intermediate Similarity |
NPD9717 |
Approved |
0.7414 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7414 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7397 |
Intermediate Similarity |
NPD1651 |
Approved |
0.7397 |
Intermediate Similarity |
NPD5691 |
Approved |
0.7391 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7389 |
Intermediate Similarity |
NPD2438 |
Suspended |
0.7378 |
Intermediate Similarity |
NPD7458 |
Discontinued |
0.7374 |
Intermediate Similarity |
NPD4287 |
Approved |
0.7371 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7368 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7368 |
Intermediate Similarity |
NPD6832 |
Phase 2 |
0.7366 |
Intermediate Similarity |
NPD7435 |
Discontinued |
0.7365 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7362 |
Intermediate Similarity |
NPD5403 |
Approved |
0.736 |
Intermediate Similarity |
NPD8150 |
Discontinued |
0.7347 |
Intermediate Similarity |
NPD17 |
Approved |
0.7346 |
Intermediate Similarity |
NPD5401 |
Approved |
0.733 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7325 |
Intermediate Similarity |
NPD4308 |
Phase 3 |
0.7325 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.731 |
Intermediate Similarity |
NPD9493 |
Approved |
0.7303 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7301 |
Intermediate Similarity |
NPD6273 |
Approved |
0.7297 |
Intermediate Similarity |
NPD6776 |
Approved |
0.7297 |
Intermediate Similarity |
NPD6781 |
Approved |
0.7297 |
Intermediate Similarity |
NPD6777 |
Approved |
0.7297 |
Intermediate Similarity |
NPD6782 |
Approved |
0.7297 |
Intermediate Similarity |
NPD6779 |
Approved |
0.7297 |
Intermediate Similarity |
NPD6778 |
Approved |
0.7297 |
Intermediate Similarity |
NPD6780 |
Approved |
0.729 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7289 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.7278 |
Intermediate Similarity |
NPD2531 |
Phase 2 |
0.7277 |
Intermediate Similarity |
NPD7782 |
Clinical (unspecified phase) |
0.7277 |
Intermediate Similarity |
NPD7783 |
Phase 2 |
0.7273 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7263 |
Intermediate Similarity |
NPD8434 |
Phase 2 |
0.7262 |
Intermediate Similarity |
NPD4288 |
Approved |
0.725 |
Intermediate Similarity |
NPD2654 |
Approved |
0.7248 |
Intermediate Similarity |
NPD1611 |
Approved |
0.7248 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7241 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.72 |
Intermediate Similarity |
NPD9269 |
Phase 2 |
0.7193 |
Intermediate Similarity |
NPD6746 |
Phase 2 |
0.7181 |
Intermediate Similarity |
NPD7698 |
Approved |
0.7181 |
Intermediate Similarity |
NPD7697 |
Approved |
0.7181 |
Intermediate Similarity |
NPD7696 |
Phase 3 |
0.7175 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7171 |
Intermediate Similarity |
NPD2797 |
Approved |
0.717 |
Intermediate Similarity |
NPD4476 |
Approved |
0.717 |
Intermediate Similarity |
NPD4477 |
Approved |
0.7168 |
Intermediate Similarity |
NPD5242 |
Approved |
0.7162 |
Intermediate Similarity |
NPD9268 |
Approved |
0.7161 |
Intermediate Similarity |
NPD3268 |
Approved |
0.7143 |
Intermediate Similarity |
NPD7870 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7143 |
Intermediate Similarity |
NPD7871 |
Phase 2 |
0.7135 |
Intermediate Similarity |
NPD7875 |
Clinical (unspecified phase) |
0.7135 |
Intermediate Similarity |
NPD7874 |
Approved |
0.7125 |
Intermediate Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.7125 |
Intermediate Similarity |
NPD6004 |
Phase 3 |
0.7125 |
Intermediate Similarity |
NPD6002 |
Phase 3 |
0.7125 |
Intermediate Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.7125 |
Intermediate Similarity |
NPD6005 |
Phase 3 |
0.7124 |
Intermediate Similarity |
NPD2798 |
Approved |
0.7124 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7124 |
Intermediate Similarity |
NPD1019 |
Discontinued |
0.7114 |
Intermediate Similarity |
NPD1778 |
Approved |
0.7112 |
Intermediate Similarity |
NPD7501 |
Clinical (unspecified phase) |
0.711
|
Intermediate Similarity |
NPD3787 |
Discontinued |